Latest Conference

Reframe psychosis as upstream glutamate-GABA circuit imbalance, with dopamine disruption downstream; muscarinic drugs reduce symptoms and boost cognition.

Clinics must adapt to REMS-style models as esketamine teaches supervision and reimbursement lessons ahead of psilocybin’s potential FDA clearance.

Motivational interviewing helps clinicians address antipsychotic ambivalence, using open-ended questions to connect LAIs or clozapine to patient goals over time.

Psychedelic trials may face blinding failures; concerns around FDA safeguards, active comparators, and filmed sessions.

Ending the REMS cut the paperwork, but reimbursement that ignores clozapine’s added care demands still keeps the drug from patients who could benefit.

Psychedelic psychiatry gains momentum as clinicians weigh evidence, safety, and stigma.

Christoph U. Correll, MD, explains how a new class of muscarinic agents lowers dopamine in specific brain regions without blocking dopamine receptors.

George Grossberg, MD, reviews how accurate the first FDA-cleared Alzheimer blood test is and which patient factors can skew its results.

Anita Clayton, MD, explains why sexual dysfunction affects most patients with major depression and how it overlaps with anhedonia.

Blood-based biomarkers are helping clinicians move past vague dementia diagnoses, but an expert says the tests belong only after a full workup in patients with objective impairment.

Christoph U. Correll, MD, says prescriber discomfort, more than patient factors, drives low LAI use in schizophrenia, and urges clinicians to present injectables as support for autonomy.

Anita Clayton, MD, explains how anhedonia points to past trauma and to future suicide and relapse risk, and how clinicians can screen for it quickly.

Christoph Correll, MD, explains why asking "How many doses have you missed?" works better than "Are you taking your medication?" and how to address the reasons behind missed doses.

An esketamine expert reflects on 7 years of nasal spray use and asks why racemic ketamine faces none of the same rules.

Explore tailored MDD augmentation strategies, balancing antipsychotic side effects, cautious dosing in older adults, and when to consider ketamine after partial response.

Why psychiatry might miss daytime sleepiness; assess sleep debt, scale scores, and sedating meds, deprescribe wisely, and rule out sleep apnea before stimulants.

Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.

Real-world data show Lybalvi cuts acute care visits in schizophrenia or bipolar I with AUD, while long-acting aripiprazole offers flexible dosing and stable symptom control.

Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.

New evidence links hippocampal “internally generated” activity to memory and psychosis, suggesting new network-based models for schizophrenia.

Hippocampal “tuplets” build predictive sequences; sleep rapidly rewires schemas for insight learning, offering clues to schizophrenia hallucinations.

Xanomeline-trospium targets muscarinic receptors for schizophrenia relief with fewer side effects, and early data suggest cognitive gains.

Cobenfy revived shelved muscarinic therapy for schizophrenia, easing side effects while boosting negative and cognitive symptoms across trials.

Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.

Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.

Explore how TMS might be useful in treating schizophrenia, and how researchers are working to localize target areas.

Causal lesion and stimulation studies map psychosis to hippocampus–thalamus circuits, pointing to a reproducible TMS target for schizophrenia symptoms.

Adolescent synaptic pruning may fuel schizophrenia; researchers explore how restoring plasticity could ease fixed delusions.